Sarepta Therapeutics (NASDAQ: SRPT) Eteplirsen may be reviewed by an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA Rumors Trader Talk

Roth Capital Reiterates Buy on Sarepta Therapeutics (SRPT) as Advisory Meeting Set for January 22nd October 15, 2015 9:52 AM BioMarin Pharma (BMRN) Announces FDA Committee Review of Drisapersen NDA in DMD Amenable to Exon 51 SkippingOctober 15, 2015 7:56 AM Sarepta Therapeutics (SRPT) Announces Tentative Scheduling of FDA Review for Eteplirsen in DMDOctober 14, 2015 12:44 PM BioMarin's (BMRN) Drisparsen Advisory Committee Meeting Set for Nov. 24 October 14, 2015 9:16 AM